Literature DB >> 20625155

Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Andrew G S Warrilow1, Claire M Martel, Josie E Parker, Nadja Melo, David C Lamb, W David Nes, Diane E Kelly, Steven L Kelly.   

Abstract

Purified Candida albicans sterol 14-α demethylase (CaCYP51) bound the CYP51 substrates lanosterol and eburicol, producing type I binding spectra with K(s) values of 11 and 25 μM, respectively, and a K(m) value of 6 μM for lanosterol. Azole binding to CaCYP51 was "tight" with both the type II spectral intensity (ΔA(max)) and the azole concentration required to obtain a half-ΔA(max) being proportional to the CaCYP51 concentration. Tight binding of fluconazole and itraconazole was confirmed by 50% inhibitory concentration determinations from CYP51 reconstitution assays. CaCYP51 had similar affinities for clotrimazole, econazole, itraconazole, ketoconazole, miconazole, and voriconazole, with K(d) values of 10 to 26 μM under oxidative conditions, compared with 47 μM for fluconazole. The affinities of CaCYP51 for fluconazole and itraconazole appeared to be 4- and 2-fold lower based on CO displacement studies than those when using direct ligand binding under oxidative conditions. Econazole and miconazole were most readily displaced by carbon monoxide, followed by clotrimazole, ketoconazole, and fluconazole, and then voriconazole (7.8 pmol min(-1)), but itraconzole could not be displaced by carbon monoxide. This work reports in depth the characterization of the azole binding properties of wild-type C. albicans CYP51, including that of voriconazole, and will contribute to effective screening of new therapeutic azole antifungal agents. Preliminary comparative studies with the I471T CaCYP51 protein suggested that fluconazole resistance conferred by this mutation was through a combination of increased turnover, increased affinity for substrate, and a reduced affinity for fluconazole in the presence of substrate, allowing the enzyme to remain functionally active, albeit at reduced velocity, at higher fluconazole concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625155      PMCID: PMC2944560          DOI: 10.1128/AAC.00587-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.

Authors:  Andrew G S Warrilow; Colin J Jackson; Josie E Parker; Timothy H Marczylo; Diane E Kelly; David C Lamb; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

2.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy.

Authors:  C R Jefcoate
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

3.  Ligand interactions with cytochrome P-450. I. Binding of primary amines.

Authors:  C R Jefcoate; J L Gaylor; R L Calabrese
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

4.  Metabolism of 32-hydroxy-24,25-dihydrolanosterol by purified cytochrome P-45014DM from yeast. Evidence for contribution of the cytochrome to whole process of lanosterol 14 alpha-demethylation.

Authors:  Y Aoyama; Y Yoshida; Y Sonoda; Y Sato
Journal:  J Biol Chem       Date:  1987-01-25       Impact factor: 5.157

5.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

Authors:  J F Morrison
Journal:  Biochim Biophys Acta       Date:  1969

6.  Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Authors:  Larissa M Podust; Hugues Ouellet; Jens P von Kries; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

7.  Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology.

Authors:  Aouatef Bellamine; Galina I Lepesheva; Michael R Waterman
Journal:  J Lipid Res       Date:  2004-08-16       Impact factor: 5.922

8.  CYP51 from Trypanosoma brucei is obtusifoliol-specific.

Authors:  Galina I Lepesheva; W David Nes; Wenxu Zhou; George C Hill; Michael R Waterman
Journal:  Biochemistry       Date:  2004-08-24       Impact factor: 3.162

9.  Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.

Authors:  Galina I Lepesheva; Hee-Won Park; Tatiana Y Hargrove; Benoit Vanhollebeke; Zdzislaw Wawrzak; Joel M Harp; Munirathinam Sundaramoorthy; W David Nes; Etienne Pays; Minu Chaudhuri; Fernando Villalta; Michael R Waterman
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

10.  The construction and characterization of self-sufficient lanosterol 14-demethylase fusion proteins consisting of yeast CYP51 and its reductase.

Authors:  Yutaka Kitahama; Masashi Nakamura; Yuzo Yoshida; Yuri Aoyama
Journal:  Biol Pharm Bull       Date:  2009-04       Impact factor: 2.233

View more
  42 in total

1.  Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; W David Nes; Michael R Waterman; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 2.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

3.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

4.  Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans.

Authors:  Aaron D Mood; Ilandari Dewage Udara Anulal Premachandra; Stanley Hiew; Fuqiang Wang; Kevin A Scott; Nathan J Oldenhuis; Haoping Liu; David L Van Vranken
Journal:  ACS Med Chem Lett       Date:  2017-01-11       Impact factor: 4.345

5.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 6.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

7.  Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.

Authors:  Athanasios Chatzimoschou; Aspasia Katragkou; Maria Simitsopoulou; Charalampos Antachopoulos; Elpiniki Georgiadou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

8.  Azole derivatives with naphthalene showing potent antifungal effects against planktonic and biofilm forms of Candida spp.: an in vitro and in silico study.

Authors:  Suat Sari; Ebru Koçak; Didem Kart; Zeynep Özdemir; M Fahir Acar; Burcu Sayoğlu; Arzu Karakurt; Sevim Dalkara
Journal:  Int Microbiol       Date:  2020-09-05       Impact factor: 2.479

9.  Novel Substrate Specificity and Temperature-Sensitive Activity of Mycosphaerella graminicola CYP51 Supported by the Native NADPH Cytochrome P450 Reductase.

Authors:  Claire L Price; Andrew G S Warrilow; Josie E Parker; Jonathan G L Mullins; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Appl Environ Microbiol       Date:  2015-03-06       Impact factor: 4.792

10.  The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Nathan P Wiederhold; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.